SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

NovaBay Pharmaceuticals, Inc. – ‘10-Q’ for 9/30/23 – ‘XML’

On:  Thursday, 11/9/23, at 4:10pm ET   ·   For:  9/30/23   ·   Accession #:  1437749-23-31256   ·   File #:  1-33678

Previous ‘10-Q’:  ‘10-Q’ on 8/10/23 for 6/30/23   ·   Next & Latest:  ‘10-Q’ on 5/9/24 for 3/31/24   ·   13 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

11/09/23  NovaBay Pharmaceuticals, Inc.     10-Q        9/30/23   95:10M                                    RDG Filings/FA

Quarterly Report   —   Form 10-Q

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   1.87M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     30K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     30K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     27K 
 5: EX-32.2     Certification -- §906 - SOA'02                      HTML     27K 
11: R1          Document And Entity Information                     HTML     79K 
12: R2          Condensed Consolidated Balance Sheets (Current      HTML    125K 
                Period Unaudited)                                                
13: R3          Condensed Consolidated Balance Sheets (Current      HTML     54K 
                Period Unaudited) (Parentheticals)                               
14: R4          Condensed Consolidated Statements of Operations     HTML     98K 
                (Unaudited)                                                      
15: R5          Condensed Consolidated Statements of Stockholders'  HTML    161K 
                Equity (Unaudited)                                               
16: R6          Condensed Consolidated Statements of Cash Flows     HTML    138K 
                (Unaudited)                                                      
17: R7          Note 1 - Organization                               HTML     39K 
18: R8          Note 2 - Summary of Significant Accounting          HTML    144K 
                Policies                                                         
19: R9          Note 3 - Fair Value Measurements                    HTML     76K 
20: R10         Note 4 - Prepaid Expenses and Other Current Assets  HTML     38K 
21: R11         Note 5 - Inventory                                  HTML     35K 
22: R12         Note 6 - Property and Equipment                     HTML     39K 
23: R13         Note 7 - Other Intangible Assets                    HTML     64K 
24: R14         Note 8 - Accrued Liabilities                        HTML     38K 
25: R15         Note 9 - Convertible Note                           HTML     58K 
26: R16         Note 10 - Commitments and Contingencies             HTML     57K 
27: R17         Note 11 - Warrant Liability                         HTML     82K 
28: R18         Note 12 - Stockholders' Equity                      HTML    149K 
29: R19         Note 13 - Equity-based Compensation                 HTML     83K 
30: R20         Note 14 - Distribution Agreements                   HTML     45K 
31: R21         Note 15 - Employee Benefit Plan                     HTML     33K 
32: R22         Note 16 - Related Party Transactions                HTML     47K 
33: R23         Note 17 - Segment Reporting                         HTML     88K 
34: R24         Note 18 - Subsequent Events                         HTML     30K 
35: R25         Significant Accounting Policies (Policies)          HTML    198K 
36: R26         Note 2 - Summary of Significant Accounting          HTML     90K 
                Policies (Tables)                                                
37: R27         Note 3 - Fair Value Measurements (Tables)           HTML     71K 
38: R28         Note 4 - Prepaid Expenses and Other Current Assets  HTML     38K 
                (Tables)                                                         
39: R29         Note 5 - Inventory (Tables)                         HTML     35K 
40: R30         Note 6 - Property and Equipment (Tables)            HTML     37K 
41: R31         Note 7 - Other Intangible Assets (Tables)           HTML     64K 
42: R32         Note 8 - Accrued Liabilities (Tables)               HTML     37K 
43: R33         Note 9 - Convertible Note (Tables)                  HTML     49K 
44: R34         Note 10 - Commitments and Contingencies (Tables)    HTML     50K 
45: R35         Note 11 - Warrant Liability (Tables)                HTML     71K 
46: R36         Note 12 - Stockholders' Equity (Tables)             HTML    110K 
47: R37         Note 13 - Equity-based Compensation (Tables)        HTML     73K 
48: R38         Note 14 - Distribution Agreements (Tables)          HTML     38K 
49: R39         Note 16 - Related Party Transactions (Tables)       HTML     42K 
50: R40         Note 17 - Segment Reporting (Tables)                HTML     83K 
51: R41         Note 1 - Organization (Details Textual)             HTML     30K 
52: R42         Note 2 - Summary of Significant Accounting          HTML     70K 
                Policies (Details Textual)                                       
53: R43         Note 2 - Summary of Significant Accounting          HTML     35K 
                Policies - Components of Cash, Cash Equivalents,                 
                and Restricted Cash (Details)                                    
54: R44         Note 2 - Summary of Significant Accounting          HTML     41K 
                Policies - Disaggregation of Revenue (Details)                   
55: R45         Note 2 - Summary of Significant Accounting          HTML     40K 
                Policies - Revenues and Accounts Receivable from                 
                Major Distribution Partners and Customers                        
                (Details)                                                        
56: R46         Note 2 - Summary of Significant Accounting          HTML     60K 
                Policies - Calculation of Basic and Diluted EPS                  
                (Details)                                                        
57: R47         Note 2 - Summary of Significant Accounting          HTML     36K 
                Policies - Outstanding Stock Options and Stock                   
                Warrants Excluded from the Diluted Net Loss Per                  
                Share Computation (Details)                                      
58: R48         Note 3 - Fair Value Measurements - Assets and       HTML     39K 
                Liabilities Measured at Fair Value on a Recurring                
                Basis (Details)                                                  
59: R49         Note 4 - Prepaid Expenses and Other Current Assets  HTML     41K 
                - Summary of Prepaid Expenses and Other Current                  
                Assets (Details)                                                 
60: R50         Note 5 - Inventory - Summary of Inventory           HTML     34K 
                (Details)                                                        
61: R51         Note 6 - Property and Equipment (Details Textual)   HTML     27K 
62: R52         Note 6 - Property and Equipment - Summary of        HTML     41K 
                Property and Equipment (Details)                                 
63: R53         Note 7 - Other Intangible Assets (Details Textual)  HTML     34K 
64: R54         Note 7 - Other Intangible Assets - Schedule of      HTML     50K 
                Finite-lived Intangible Assets (Details)                         
65: R55         Note 7 - Other Intangible Assets - Schedule of      HTML     38K 
                Finite-Lived Intangible Assets, Future                           
                Amortization Expense (Details)                                   
66: R56         Note 8 - Accrued Liabilities - Summary of Accrued   HTML     39K 
                Liabilities (Details)                                            
67: R57         Note 9 - Convertible Note (Details Textual)         HTML     91K 
68: R58         Note 9 - Convertible Note - Key Assumptions of      HTML     36K 
                Combined Embedded Derivative (Details)                           
69: R59         Note 9 - Convertible Note - Debenture (Details)     HTML     37K 
70: R60         Note 9 - Convertible Note - Contractual Maturity    HTML     35K 
                (Details)                                                        
71: R61         Note 10 - Commitments and Contingencies (Details    HTML     28K 
                Textual)                                                         
72: R62         Note 10 - Commitments and Contingencies - Lease     HTML     35K 
                Expense (Details)                                                
73: R63         Note 10 - Commitments and Contingencies - Schedule  HTML     46K 
                of Future Lease Payments (Details)                               
74: R64         Note 11 - Warrant Liability (Details Textual)       HTML     50K 
75: R65         Note 11 - Warrant Liability - The Key Assumptions   HTML     90K 
                Used to Value the Warrants (Details)                             
76: R66         Note 12 - Stockholders' Equity (Details Textual)    HTML    271K 
77: R67         Note 12 - Stockholders' Equity - The Key            HTML     70K 
                Assumptions Used to Value the Warrants (Details)                 
78: R68         Note 12 - Stockholders' Equity - Preferred Stock    HTML     47K 
                Assumptions (Details)                                            
79: R69         Note 12 - Stockholders' Equity - Outstanding        HTML     37K 
                Warrants (Details)                                               
80: R70         Note 13 - Equity-based Compensation (Details        HTML     87K 
                Textual)                                                         
81: R71         Note 13 - Equity-based Compensation - Stock         HTML     76K 
                Options Outstanding (Details)                                    
82: R72         Note 13 - Equity-based Compensation -               HTML     38K 
                Weighted-average Assumptions Used in Determining                 
                the Value of Options Granted to Employees and                    
                Directors (Details)                                              
83: R73         Note 13 - Equity-based Compensation - Summary of    HTML     33K 
                Stock-based Compensation Expense Included in                     
                Results of Operations (Details)                                  
84: R74         Note 14 - Distribution Agreements (Details          HTML     48K 
                Textual)                                                         
85: R75         Note 14 - Distribution Agreements - Changes in      HTML     40K 
                Assets and Liabilities (Details)                                 
86: R76         Note 15 - Employee Benefit Plan (Details Textual)   HTML     37K 
87: R77         Note 16 - Related Party Transactions (Details       HTML     29K 
                Textual)                                                         
88: R78         Note 16 - Related Party Transactions - Related      HTML     37K 
                Party Revenue, Cost of Goods Sold, and Expenses                  
                (Details)                                                        
89: R79         Note 17 - Segment Reporting (Details Textual)       HTML     27K 
90: R80         Note 17 - Segment Reporting - Financial             HTML     46K 
                Information by Segment (Details)                                 
93: XML         IDEA XML File -- Filing Summary                      XML    181K 
91: XML         XBRL Instance -- nby20230930_10q_htm                 XML   3.03M 
92: EXCEL       IDEA Workbook of Financial Report Info              XLSX    178K 
 7: EX-101.CAL  XBRL Calculations -- nby-20230930_cal                XML    149K 
 8: EX-101.DEF  XBRL Definitions -- nby-20230930_def                 XML   1.59M 
 9: EX-101.LAB  XBRL Labels -- nby-20230930_lab                      XML   1.22M 
10: EX-101.PRE  XBRL Presentations -- nby-20230930_pre               XML   1.63M 
 6: EX-101.SCH  XBRL Schema -- nby-20230930                          XSD    268K 
94: JSON        XBRL Instance as JSON Data -- MetaLinks              522±   861K 
95: ZIP         XBRL Zipped Folder -- 0001437749-23-031256-xbrl      Zip    313K

‘XML’   —   IDEA XML File — Filing Summary

This Document is an IDEA XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<FilingSummary>
<Version> 3.23.3 </Version>
<ProcessingTime/>
<ReportFormat> html </ReportFormat>
<ContextCount> 553 </ContextCount>
<ElementCount> 358 </ElementCount>
<EntityCount> 1 </EntityCount>
<FootnotesReported> true </FootnotesReported>
<SegmentCount> 114 </SegmentCount>
<ScenarioCount> 0 </ScenarioCount>
<TuplesReported> false </TuplesReported>
<UnitCount> 8 </UnitCount>
<MyReports>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R1.htm </HtmlFileName>
<LongName> 000 - Document - Document And Entity Information </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-document-and-entity-information </Role>
<ShortName> Document And Entity Information </ShortName>
<MenuCategory> Cover </MenuCategory>
<Position> 1 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R2.htm </HtmlFileName>
<LongName> 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited </Role>
<ShortName> Condensed Consolidated Balance Sheets (Current Period Unaudited) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 2 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R3.htm </HtmlFileName>
<LongName> 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals </Role>
<ShortName> Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 3 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R4.htm </HtmlFileName>
<LongName> 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-condensed-consolidated-statements-of-operations-unaudited </Role>
<ShortName> Condensed Consolidated Statements of Operations (Unaudited) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 4 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R5.htm </HtmlFileName>
<LongName> 004 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-condensed-consolidated-statements-of-stockholders-equity-unaudited </Role>
<ShortName> Condensed Consolidated Statements of Stockholders' Equity (Unaudited) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 5 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R6.htm </HtmlFileName>
<LongName> 005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited </Role>
<ShortName> Condensed Consolidated Statements of Cash Flows (Unaudited) </ShortName>
<MenuCategory> Statements </MenuCategory>
<Position> 6 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R7.htm </HtmlFileName>
<LongName> 006 - Disclosure - Note 1 - Organization </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-1-organization </Role>
<ShortName> Note 1 - Organization </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 7 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R8.htm </HtmlFileName>
<LongName> 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 8 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R9.htm </HtmlFileName>
<LongName> 008 - Disclosure - Note 3 - Fair Value Measurements </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-3-fair-value-measurements </Role>
<ShortName> Note 3 - Fair Value Measurements </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 9 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R10.htm </HtmlFileName>
<LongName> 009 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets </Role>
<ShortName> Note 4 - Prepaid Expenses and Other Current Assets </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 10 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R11.htm </HtmlFileName>
<LongName> 010 - Disclosure - Note 5 - Inventory </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-5-inventory </Role>
<ShortName> Note 5 - Inventory </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 11 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R12.htm </HtmlFileName>
<LongName> 011 - Disclosure - Note 6 - Property and Equipment </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-6-property-and-equipment </Role>
<ShortName> Note 6 - Property and Equipment </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 12 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R13.htm </HtmlFileName>
<LongName> 012 - Disclosure - Note 7 - Other Intangible Assets </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-7-other-intangible-assets </Role>
<ShortName> Note 7 - Other Intangible Assets </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 13 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R14.htm </HtmlFileName>
<LongName> 013 - Disclosure - Note 8 - Accrued Liabilities </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-8-accrued-liabilities </Role>
<ShortName> Note 8 - Accrued Liabilities </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 14 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R15.htm </HtmlFileName>
<LongName> 014 - Disclosure - Note 9 - Convertible Note </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-9-convertible-note </Role>
<ShortName> Note 9 - Convertible Note </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 15 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R16.htm </HtmlFileName>
<LongName> 015 - Disclosure - Note 10 - Commitments and Contingencies </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-10-commitments-and-contingencies </Role>
<ShortName> Note 10 - Commitments and Contingencies </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 16 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R17.htm </HtmlFileName>
<LongName> 016 - Disclosure - Note 11 - Warrant Liability </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-11-warrant-liability </Role>
<ShortName> Note 11 - Warrant Liability </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 17 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R18.htm </HtmlFileName>
<LongName> 017 - Disclosure - Note 12 - Stockholders' Equity </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-12-stockholders-equity </Role>
<ShortName> Note 12 - Stockholders' Equity </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 18 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R19.htm </HtmlFileName>
<LongName> 018 - Disclosure - Note 13 - Equity-based Compensation </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-13-equitybased-compensation </Role>
<ShortName> Note 13 - Equity-based Compensation </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 19 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R20.htm </HtmlFileName>
<LongName> 019 - Disclosure - Note 14 - Distribution Agreements </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-14-distribution-agreements- </Role>
<ShortName> Note 14 - Distribution Agreements </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 20 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R21.htm </HtmlFileName>
<LongName> 020 - Disclosure - Note 15 - Employee Benefit Plan </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-15-employee-benefit-plan </Role>
<ShortName> Note 15 - Employee Benefit Plan </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 21 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R22.htm </HtmlFileName>
<LongName> 021 - Disclosure - Note 16 - Related Party Transactions </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-16-related-party-transactions </Role>
<ShortName> Note 16 - Related Party Transactions </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 22 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R23.htm </HtmlFileName>
<LongName> 022 - Disclosure - Note 17 - Segment Reporting </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-17-segment-reporting </Role>
<ShortName> Note 17 - Segment Reporting </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 23 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R24.htm </HtmlFileName>
<LongName> 023 - Disclosure - Note 18 - Subsequent Events </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-18-subsequent-events </Role>
<ShortName> Note 18 - Subsequent Events </ShortName>
<MenuCategory> Notes </MenuCategory>
<Position> 24 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R25.htm </HtmlFileName>
<LongName> 024 - Disclosure - Significant Accounting Policies (Policies) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-significant-accounting-policies-policies </Role>
<ShortName> Significant Accounting Policies (Policies) </ShortName>
<MenuCategory> Policies </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies </ParentRole>
<Position> 25 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R26.htm </HtmlFileName>
<LongName> 025 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies-tables </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies </ParentRole>
<Position> 26 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R27.htm </HtmlFileName>
<LongName> 026 - Disclosure - Note 3 - Fair Value Measurements (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-3-fair-value-measurements-tables </Role>
<ShortName> Note 3 - Fair Value Measurements (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-3-fair-value-measurements </ParentRole>
<Position> 27 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R28.htm </HtmlFileName>
<LongName> 027 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-tables </Role>
<ShortName> Note 4 - Prepaid Expenses and Other Current Assets (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets </ParentRole>
<Position> 28 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R29.htm </HtmlFileName>
<LongName> 028 - Disclosure - Note 5 - Inventory (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-5-inventory-tables </Role>
<ShortName> Note 5 - Inventory (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-5-inventory </ParentRole>
<Position> 29 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R30.htm </HtmlFileName>
<LongName> 029 - Disclosure - Note 6 - Property and Equipment (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-6-property-and-equipment-tables </Role>
<ShortName> Note 6 - Property and Equipment (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-6-property-and-equipment </ParentRole>
<Position> 30 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R31.htm </HtmlFileName>
<LongName> 030 - Disclosure - Note 7 - Other Intangible Assets (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-7-other-intangible-assets-tables </Role>
<ShortName> Note 7 - Other Intangible Assets (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-7-other-intangible-assets </ParentRole>
<Position> 31 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R32.htm </HtmlFileName>
<LongName> 031 - Disclosure - Note 8 - Accrued Liabilities (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-8-accrued-liabilities-tables </Role>
<ShortName> Note 8 - Accrued Liabilities (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-8-accrued-liabilities </ParentRole>
<Position> 32 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R33.htm </HtmlFileName>
<LongName> 032 - Disclosure - Note 9 - Convertible Note (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-9-convertible-note-tables </Role>
<ShortName> Note 9 - Convertible Note (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-9-convertible-note </ParentRole>
<Position> 33 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R34.htm </HtmlFileName>
<LongName> 033 - Disclosure - Note 10 - Commitments and Contingencies (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-10-commitments-and-contingencies-tables </Role>
<ShortName> Note 10 - Commitments and Contingencies (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-10-commitments-and-contingencies </ParentRole>
<Position> 34 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R35.htm </HtmlFileName>
<LongName> 034 - Disclosure - Note 11 - Warrant Liability (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-11-warrant-liability-tables </Role>
<ShortName> Note 11 - Warrant Liability (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-11-warrant-liability </ParentRole>
<Position> 35 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R36.htm </HtmlFileName>
<LongName> 035 - Disclosure - Note 12 - Stockholders' Equity (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-12-stockholders-equity-tables </Role>
<ShortName> Note 12 - Stockholders' Equity (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-12-stockholders-equity </ParentRole>
<Position> 36 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R37.htm </HtmlFileName>
<LongName> 036 - Disclosure - Note 13 - Equity-based Compensation (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-13-equitybased-compensation-tables </Role>
<ShortName> Note 13 - Equity-based Compensation (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-13-equitybased-compensation </ParentRole>
<Position> 37 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R38.htm </HtmlFileName>
<LongName> 037 - Disclosure - Note 14 - Distribution Agreements (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-14-distribution-agreements-tables </Role>
<ShortName> Note 14 - Distribution Agreements (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-14-distribution-agreements- </ParentRole>
<Position> 38 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R39.htm </HtmlFileName>
<LongName> 038 - Disclosure - Note 16 - Related Party Transactions (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-16-related-party-transactions-tables </Role>
<ShortName> Note 16 - Related Party Transactions (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-16-related-party-transactions </ParentRole>
<Position> 39 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R40.htm </HtmlFileName>
<LongName> 039 - Disclosure - Note 17 - Segment Reporting (Tables) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-17-segment-reporting-tables </Role>
<ShortName> Note 17 - Segment Reporting (Tables) </ShortName>
<MenuCategory> Tables </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-17-segment-reporting </ParentRole>
<Position> 40 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R41.htm </HtmlFileName>
<LongName> 040 - Disclosure - Note 1 - Organization (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-1-organization-details-textual </Role>
<ShortName> Note 1 - Organization (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-1-organization </ParentRole>
<Position> 41 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R42.htm </HtmlFileName>
<LongName> 041 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies-details-textual </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies-tables </ParentRole>
<Position> 42 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R43.htm </HtmlFileName>
<LongName> 042 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies-components-of-cash-cash-equivalents-and-restricted-cash-details </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 43 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R44.htm </HtmlFileName>
<LongName> 043 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies-disaggregation-of-revenue-details </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 44 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R45.htm </HtmlFileName>
<LongName> 044 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies-revenues-and-accounts-receivable-from-major-distribution-partners-and-customers-details </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable from Major Distribution Partners and Customers (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 45 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R46.htm </HtmlFileName>
<LongName> 045 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies-calculation-of-basic-and-diluted-eps-details </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 46 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R47.htm </HtmlFileName>
<LongName> 046 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-2-summary-of-significant-accounting-policies-outstanding-stock-options-and-stock-warrants-excluded-from-the-diluted-net-loss-per-share-computation-details </Role>
<ShortName> Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded from the Diluted Net Loss Per Share Computation (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 47 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R48.htm </HtmlFileName>
<LongName> 047 - Disclosure - Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-3-fair-value-measurements-assets-and-liabilities-measured-at-fair-value-on-a-recurring-basis-details </Role>
<ShortName> Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 48 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R49.htm </HtmlFileName>
<LongName> 048 - Disclosure - Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-4-prepaid-expenses-and-other-current-assets-summary-of-prepaid-expenses-and-other-current-assets-details </Role>
<ShortName> Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 49 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R50.htm </HtmlFileName>
<LongName> 049 - Disclosure - Note 5 - Inventory - Summary of Inventory (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-5-inventory-summary-of-inventory-details </Role>
<ShortName> Note 5 - Inventory - Summary of Inventory (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 50 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R51.htm </HtmlFileName>
<LongName> 050 - Disclosure - Note 6 - Property and Equipment (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-6-property-and-equipment-details-textual </Role>
<ShortName> Note 6 - Property and Equipment (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-6-property-and-equipment-tables </ParentRole>
<Position> 51 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R52.htm </HtmlFileName>
<LongName> 051 - Disclosure - Note 6 - Property and Equipment - Summary of Property and Equipment (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-6-property-and-equipment-summary-of-property-and-equipment-details </Role>
<ShortName> Note 6 - Property and Equipment - Summary of Property and Equipment (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 52 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R53.htm </HtmlFileName>
<LongName> 052 - Disclosure - Note 7 - Other Intangible Assets (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-7-other-intangible-assets-details-textual </Role>
<ShortName> Note 7 - Other Intangible Assets (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-7-other-intangible-assets-tables </ParentRole>
<Position> 53 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R54.htm </HtmlFileName>
<LongName> 053 - Disclosure - Note 7 - Other Intangible Assets - Schedule of Finite-lived Intangible Assets (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-7-other-intangible-assets-schedule-of-finitelived-intangible-assets-details </Role>
<ShortName> Note 7 - Other Intangible Assets - Schedule of Finite-lived Intangible Assets (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 54 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R55.htm </HtmlFileName>
<LongName> 054 - Disclosure - Note 7 - Other Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-7-other-intangible-assets-schedule-of-finitelived-intangible-assets-future-amortization-expense-details </Role>
<ShortName> Note 7 - Other Intangible Assets - Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 55 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R56.htm </HtmlFileName>
<LongName> 055 - Disclosure - Note 8 - Accrued Liabilities - Summary of Accrued Liabilities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-8-accrued-liabilities-summary-of-accrued-liabilities-details </Role>
<ShortName> Note 8 - Accrued Liabilities - Summary of Accrued Liabilities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 56 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R57.htm </HtmlFileName>
<LongName> 056 - Disclosure - Note 9 - Convertible Note (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-9-convertible-note-details-textual </Role>
<ShortName> Note 9 - Convertible Note (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-9-convertible-note-tables </ParentRole>
<Position> 57 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R58.htm </HtmlFileName>
<LongName> 057 - Disclosure - Note 9 - Convertible Note - Key Assumptions of Combined Embedded Derivative (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-9-convertible-note-key-assumptions-of-combined-embedded-derivative-details </Role>
<ShortName> Note 9 - Convertible Note - Key Assumptions of Combined Embedded Derivative (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 58 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R59.htm </HtmlFileName>
<LongName> 058 - Disclosure - Note 9 - Convertible Note - Debenture (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-9-convertible-note-debenture-details </Role>
<ShortName> Note 9 - Convertible Note - Debenture (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 59 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R60.htm </HtmlFileName>
<LongName> 059 - Disclosure - Note 9 - Convertible Note - Contractual Maturity (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-9-convertible-note-contractual-maturity-details </Role>
<ShortName> Note 9 - Convertible Note - Contractual Maturity (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 60 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R61.htm </HtmlFileName>
<LongName> 060 - Disclosure - Note 10 - Commitments and Contingencies (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-10-commitments-and-contingencies-details-textual </Role>
<ShortName> Note 10 - Commitments and Contingencies (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-10-commitments-and-contingencies-tables </ParentRole>
<Position> 61 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R62.htm </HtmlFileName>
<LongName> 061 - Disclosure - Note 10 - Commitments and Contingencies - Lease Expense (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-10-commitments-and-contingencies-lease-expense-details </Role>
<ShortName> Note 10 - Commitments and Contingencies - Lease Expense (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 62 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R63.htm </HtmlFileName>
<LongName> 062 - Disclosure - Note 10 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-10-commitments-and-contingencies-schedule-of-future-lease-payments-details </Role>
<ShortName> Note 10 - Commitments and Contingencies - Schedule of Future Lease Payments (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 63 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R64.htm </HtmlFileName>
<LongName> 063 - Disclosure - Note 11 - Warrant Liability (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-11-warrant-liability-details-textual </Role>
<ShortName> Note 11 - Warrant Liability (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-11-warrant-liability-tables </ParentRole>
<Position> 64 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R65.htm </HtmlFileName>
<LongName> 064 - Disclosure - Note 11 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-11-warrant-liability-the-key-assumptions-used-to-value-the-warrants-details </Role>
<ShortName> Note 11 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 65 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R66.htm </HtmlFileName>
<LongName> 065 - Disclosure - Note 12 - Stockholders' Equity (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-12-stockholders-equity-details-textual </Role>
<ShortName> Note 12 - Stockholders' Equity (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-12-stockholders-equity-tables </ParentRole>
<Position> 66 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R67.htm </HtmlFileName>
<LongName> 066 - Disclosure - Note 12 - Stockholders' Equity - The Key Assumptions Used to Value the Warrants (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-12-stockholders-equity-the-key-assumptions-used-to-value-the-warrants-details </Role>
<ShortName> Note 12 - Stockholders' Equity - The Key Assumptions Used to Value the Warrants (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 67 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R68.htm </HtmlFileName>
<LongName> 067 - Disclosure - Note 12 - Stockholders' Equity - Preferred Stock Assumptions (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-12-stockholders-equity-preferred-stock-assumptions-details </Role>
<ShortName> Note 12 - Stockholders' Equity - Preferred Stock Assumptions (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 68 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R69.htm </HtmlFileName>
<LongName> 068 - Disclosure - Note 12 - Stockholders' Equity - Outstanding Warrants (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-12-stockholders-equity-outstanding-warrants-details </Role>
<ShortName> Note 12 - Stockholders' Equity - Outstanding Warrants (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 69 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R70.htm </HtmlFileName>
<LongName> 069 - Disclosure - Note 13 - Equity-based Compensation (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-13-equitybased-compensation-details-textual </Role>
<ShortName> Note 13 - Equity-based Compensation (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-13-equitybased-compensation-tables </ParentRole>
<Position> 70 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R71.htm </HtmlFileName>
<LongName> 070 - Disclosure - Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-13-equitybased-compensation-stock-options-outstanding-details </Role>
<ShortName> Note 13 - Equity-based Compensation - Stock Options Outstanding (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 71 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R72.htm </HtmlFileName>
<LongName> 071 - Disclosure - Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement--note-13-equitybased-compensation-weightedaverage-assumptions-used-in-determining-the-value-of-options-granted-to-employees-and-directors-details </Role>
<ShortName> Note 13 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 72 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R73.htm </HtmlFileName>
<LongName> 072 - Disclosure - Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-13-equitybased-compensation-summary-of-stockbased-compensation-expense-included-in-results-of-operations-details </Role>
<ShortName> Note 13 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 73 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R74.htm </HtmlFileName>
<LongName> 073 - Disclosure - Note 14 - Distribution Agreements (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-14-distribution-agreements-details-textual </Role>
<ShortName> Note 14 - Distribution Agreements (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-14-distribution-agreements-tables </ParentRole>
<Position> 74 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R75.htm </HtmlFileName>
<LongName> 074 - Disclosure - Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-14-distribution-agreements-changes-in-assets-and-liabilities-details </Role>
<ShortName> Note 14 - Distribution Agreements - Changes in Assets and Liabilities (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 75 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R76.htm </HtmlFileName>
<LongName> 075 - Disclosure - Note 15 - Employee Benefit Plan (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-15-employee-benefit-plan-details-textual </Role>
<ShortName> Note 15 - Employee Benefit Plan (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-15-employee-benefit-plan </ParentRole>
<Position> 76 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R77.htm </HtmlFileName>
<LongName> 076 - Disclosure - Note 16 - Related Party Transactions (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-16-related-party-transactions-details-textual </Role>
<ShortName> Note 16 - Related Party Transactions (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-16-related-party-transactions-tables </ParentRole>
<Position> 77 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R78.htm </HtmlFileName>
<LongName> 077 - Disclosure - Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-16-related-party-transactions-related-party-revenue-cost-of-goods-sold-and-expenses-details </Role>
<ShortName> Note 16 - Related Party Transactions - Related Party Revenue, Cost of Goods Sold, and Expenses (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 78 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R79.htm </HtmlFileName>
<LongName> 078 - Disclosure - Note 17 - Segment Reporting (Details Textual) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-17-segment-reporting-details-textual </Role>
<ShortName> Note 17 - Segment Reporting (Details Textual) </ShortName>
<MenuCategory> Details </MenuCategory>
<ParentRole> http://www.novabaypharma.com/20230930/role/statement-note-17-segment-reporting-tables </ParentRole>
<Position> 79 </Position>
</Report>
<Report instance="nby20230930_10q.htm">
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<HtmlFileName> R80.htm </HtmlFileName>
<LongName> 079 - Disclosure - Note 17 - Segment Reporting - Financial Information by Segment (Details) </LongName>
<ReportType> Sheet </ReportType>
<Role> http://www.novabaypharma.com/20230930/role/statement-note-17-segment-reporting-financial-information-by-segment-details </Role>
<ShortName> Note 17 - Segment Reporting - Financial Information by Segment (Details) </ShortName>
<MenuCategory> Details </MenuCategory>
<Position> 80 </Position>
</Report>
<Report>
<IsDefault> false </IsDefault>
<HasEmbeddedReports> false </HasEmbeddedReports>
<LongName> All Reports </LongName>
<ReportType> Book </ReportType>
<ShortName> All Reports </ShortName>
</Report>
</MyReports>
<InputFiles>
<File> nby-20230930.xsd </File>
<File> nby-20230930_cal.xml </File>
<File> nby-20230930_def.xml </File>
<File> nby-20230930_lab.xml </File>
<File> nby-20230930_pre.xml </File>
<File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="nby20230930_10q.htm"> nby20230930_10q.htm </File>
</InputFiles>
<SupplementalFiles/>
<BaseTaxonomies>
<BaseTaxonomy items="1063"> http://fasb.org/us-gaap/2023 </BaseTaxonomy>
<BaseTaxonomy items="29"> http://xbrl.sec.gov/dei/2023 </BaseTaxonomy>
</BaseTaxonomies>
<HasPresentationLinkbase> true </HasPresentationLinkbase>
<HasCalculationLinkbase> true </HasCalculationLinkbase>
</FilingSummary>

13 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/14/23  NovaBay Pharmaceuticals, Inc.     8-K:5,9     6/09/23   12:412K                                   RDG Filings/FA
 4/27/23  NovaBay Pharmaceuticals, Inc.     8-K:1,2,3,8 4/27/23   21:1.5M                                   RDG Filings/FA
11/18/22  NovaBay Pharmaceuticals, Inc.     8-K:1,5,9  11/14/22   13:324K                                   RDG Filings/FA
 9/13/22  NovaBay Pharmaceuticals, Inc.     8-K:1,3,8,9 9/09/22   26:1.9M                                   RDG Filings/FA
 2/01/22  NovaBay Pharmaceuticals, Inc.     8-K:5,9     1/31/22   12:170K                                   RDG Filings/FA
11/01/21  NovaBay Pharmaceuticals, Inc.     8-K:1,3,5,810/29/21   16:998K                                   RDG Filings/FA
 9/28/21  NovaBay Pharmaceuticals, Inc.     8-K:1,3,7,9 9/27/21   13:1M                                     RDG Filings/FA
 5/24/21  NovaBay Pharmaceuticals, Inc.     8-K:5,9     5/21/21    2:41K                                    RDG Filings/FA
 7/21/20  NovaBay Pharmaceuticals, Inc.     8-K:1,2,3,9 7/20/20    5:278K                                   RDG Filings/FA
 5/28/20  NovaBay Pharmaceuticals, Inc.     8-K:5,9     5/26/20    2:37K                                    RDG Filings/FA
 5/18/20  NovaBay Pharmaceuticals, Inc.     8-K:1,3,9   5/13/20    4:259K                                   RDG Filings/FA
 6/04/18  NovaBay Pharmaceuticals, Inc.     8-K:5,9     5/31/18    2:41K                                    RDG Filings/FA
 3/21/18  NovaBay Pharmaceuticals, Inc.     10-K       12/31/17   90:10M                                    RDG Filings/FA
↑Top
Filing Submission 0001437749-23-031256   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Wed., May 15, 9:33:48.2pm ET